


**MDR organisms**  
**Epidemiological study involving  
healthcare institutions, nursing  
homes and the community setting**



- 1/1 ● Regional university hospital
- 18/20 ⊙ General HCIs
- 7/18 ≡ Local HCIs
- 14/19 + Private clinics
- 12/30 ■ Rehabilitation-care centers
- 5/15 ◆ Psychiatric clinics
- 31 ◇ Nursing homes
- 19 • Outpatients' clinical laboratories

# Objectives

---

- ✦ Evaluate precisely the epidemiological state of the spread of MDR organisms into the region Centre of France
- ✦ Epidemiological study involving HCIs and the community setting
- ✦ All infections caused by MDR organisms identified during the study period documented (15 days at least)
- ✦ Strains centralized and studied (antibiotic susceptibility and genetic diversity)

# The study

---


- ◆ 346,251 patient-days
  - ◆ 164,008 in short-stay unit
  - ◆ 64,107 in rehabilitation care unit
  - ◆ 79,107 in long-stay unit
  - ◆ 38,869 in psychiatric unit
- ◆ 233,835 resident-days
- ◆ 43,379 diagnostic clinical samples
  - ◆ 7,564 blood cultures (17 %) ●
  - ◆ 2,130 deep pus (5 %) ●
  - ◆ 1,054 respiratory tract samples (2 %) ●
  - ◆ 17,768 urines (41 %) ●
  - ◆ 606 intravenous devices (1 %) ●
  - ◆ 12,889 superficial pus (30 %) ●



# 275 MDR organisms


---

- ◆ 12 different species
  - ◆ *S. aureus* (103, 37%)
  - ◆ *E. coli* (84, 31%)
  - ◆ **No VRE**
  - ◆ 25 *E. cloacae* (9 %)
  - ◆ 23 *P. aeruginosa* (8 %)
  - ◆ 13 *K. pneumoniae* (5%)
  - ◆ 7 *A. baumannii* (3%)
  - ◆ 6 *P. mirabilis* (2%)
  - ◆ 5 *C. freundii* (2%)
  - ◆ 3 *E. aerogenes* (1%)
  - ◆ 3 *C. koseri*
  - ◆ 2 *K. oxytoca*
  - ◆ 1 *K. ornithinolytica*



# MDR organisms incidence rate


Incidence rate / 1000 PD or RD



# 275 MDR organisms


---

- ◆ **155 (56%) from urine ( $p < 0.001$ )**
- ◆ 65 from superficial pus (24%)
- ◆ 23 from respiratory tract (8%)
- ◆ 14 from deep pus (5%)
- ◆ 12 from blood cultures (4%)
- ◆ one from IVD (< 1 %)
- ◆ 5 not known



# MRSA


- ✦ 71/103 “new clones” (69%)
- ✦ 57/103 FQ R-MRSA (55%)
- ✦ FQ R : 95/103 (92%)
- ✦ No GISA
- ✦ R to Mupirocin : 1/103 (1%)
- ✦ 4/103 *tst* gene +
- ✦ 1/103 *luk* genes +





# MRSA Genetic diversity

- ✦ 64 patterns /103 strains
- ✦ 1 NT
- ✦ 7 clusters
  - ✦ 6 with FQ R-MRSA
- ✦ ID<sub>H&G</sub> 0.99
  - ✦ 0.97 for FQ R-MRSA
  - ✦ 0.99 for classical MRSA



# *E. coli*


---

✦ ESBL-producing : 66/84 (79%)

✦ 56/66 (85%) : CTX-M


✦ FQ R : 51/ 84 (61%)

✦ 43/66 ESBL + (65 %)




# ESBL producing *E. coli* Genetic diversity

- ✦ 53 patterns /63 strains
- ✦ 3 NT
- ✦ 2 clusters
  - ✦ 1 with CTX-M-15 ST131
- ✦ ID<sub>H&G</sub> 0.99



# *E. coli* & Antibiotic resistance

% Resistant strains



# Likely epidemic phenomena

MRSA	<i>E. coli</i>	<i>E. cloacae</i>	<i>K. pneumoniae</i>	<i>A. baumannii</i>	<i>P. mirabilis</i>
7	4	2	1	1	1
4 Hospitals	2 BLSE+ 1 Hospital 1 NH	1 BLSE+ 1 Hospital	BLSE+ 2 Hospitals 1 Reab. C. Center	BLSE- 1 Hospital	BLSE+ 1 Hospital 1 NH Outpatients
1 Reab. C. Center	2 BLSE- 1 Hospital 1 Clinic	1 BLSE- 1 Hospital			



**MDR organisms**  
**Epidemiological study involving healthcare institutions,  
nursing homes and the community setting**

**Spread in NH**

**16 likely outbreaks**

**Low incidence**

**No outbreak with**

- VRE
- TSST-1 producing MRSA
- PVL-producing MRSA


**No GISA**

**Predominant new clones**

- CA-MRSA
- ESBL CTX-M type *E. coli*

**For both**

- from the community
- high genetic diversity
- high FQ resistance
- predominance in urine



**Multiresistant Bacteria Study Group of the Réseau des Hygiénistes du Centre**

**G. Abs, S. Alicot, P. Amirault, M. Archambault, M.-C. Audry, M.-N. Bachelier, M. Beauvais, I. Blasi, J. Bleuët, D. Bloc, M. Boucher, M. Bounioux, L. Bucquet, C. Braguy, B. Cattier, M. Chabaud-Mayer, B. Chabin, C. Chaigne, C. Chandesris, C. Chardonnal, V. Chevereau, V. Chieux, I. Cloarec, G. Courouble, M.-C. Courtin, C. De Gialluly, C. Decreux, G. Delaporte, M. Delvingt, C. Denis, F. Deperrois, F. Dieu, A. Dubouille, J. Duport, P. Durand, C. Etienne, L. Fagu, M.-C. Farcy, C. Fièvre, P. Foloppe, R. Fournier-Hoock, F. Gerrand, O. Guignard, F. Guinard, T. Gourdet, J.-L. Graveron, M.-F. Guillon, S. Guittet, P. Harriau, S. Hautefeuille, C. Hombrouck-Alet, D. Imbault, B. Jachet, D. Jehanno, S. Jouanneau, J. Journe, M.-J. Kourta, F. Laubus, P. Laudat, O. Lehiani, H. Lemaitre, A. Lepineux-Da Rocha, J.-C. Lopez, A. Mor, V. Morange, E. Morel, E. Morin, M. Morvan, C. Naudion, C. Neveu, B. Nguon, O. Paba, F. Périgois, E. Petat, M. Picart, S. Picault, C. Poireau, D. Poitvin, M. Prevost-Oussar, C. Querrien, D. Ratovohery, S. Rossard, B. Rousseau, A. Roussin, V. Salaun, M. Savoyen, A. Secher, E. Taillemite, S. Thebaut, J.-F. Théron le Gargasson, S. Thiais, D. Tran, N. van der Mee-Marquet, R. Vergez-Pascal, H. Villain, J. Villaudière, S. Watt.**